SG11202004904XA - Binding molecules that specifically bind to tau - Google Patents

Binding molecules that specifically bind to tau

Info

Publication number
SG11202004904XA
SG11202004904XA SG11202004904XA SG11202004904XA SG11202004904XA SG 11202004904X A SG11202004904X A SG 11202004904XA SG 11202004904X A SG11202004904X A SG 11202004904XA SG 11202004904X A SG11202004904X A SG 11202004904XA SG 11202004904X A SG11202004904X A SG 11202004904XA
Authority
SG
Singapore
Prior art keywords
tau
specifically bind
binding molecules
molecules
binding
Prior art date
Application number
SG11202004904XA
Inventor
Constantin Apetri
Jaroslaw Juraszek
Harmke Verveen
Roosmarijn Janson
Berdien Siregar
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11202004904XA publication Critical patent/SG11202004904XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
SG11202004904XA 2017-12-04 2018-12-04 Binding molecules that specifically bind to tau SG11202004904XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17205124 2017-12-04
PCT/EP2018/083451 WO2019110571A1 (en) 2017-12-04 2018-12-04 Binding molecules that specifically bind to tau

Publications (1)

Publication Number Publication Date
SG11202004904XA true SG11202004904XA (en) 2020-06-29

Family

ID=60569783

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004904XA SG11202004904XA (en) 2017-12-04 2018-12-04 Binding molecules that specifically bind to tau

Country Status (10)

Country Link
US (1) US20200369754A1 (en)
EP (1) EP3720490A1 (en)
JP (1) JP2021505142A (en)
KR (1) KR20200094177A (en)
CN (1) CN111447951A (en)
AU (1) AU2018380765A1 (en)
CA (1) CA3084098A1 (en)
EA (1) EA202091350A1 (en)
SG (1) SG11202004904XA (en)
WO (1) WO2019110571A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035943B1 (en) 2013-03-13 2020-09-03 Протена Биосайенсес Лимитед Antibody binding to human tau protein
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
IL262726B1 (en) 2016-05-02 2024-03-01 Prothena Biosciences Ltd Antibodies recognizing tau
EP3619233A4 (en) 2017-05-02 2021-03-03 Prothena Biosciences Limited Antibodies recognizing tau
TW202100550A (en) 2019-03-03 2021-01-01 愛爾蘭商普羅帝納生物科學公司 Antibodies recognizing tau
KR102509648B1 (en) * 2019-08-06 2023-03-15 아프리노이아 테라퓨틱스 리미티드 Antibodies that bind to pathological Tau species and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023178241A2 (en) * 2022-03-16 2023-09-21 The Regents Of The University Of Colorado A Body Corporate Methods and compositions for disrupting tau aggregates using polyserine repeat sequences targeting exogenous proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1161548T2 (en) 1999-04-15 2010-02-26 Crucell Holland Bv Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
EA031698B1 (en) * 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Human anti-tau antibodies
EP3160999B1 (en) * 2014-06-26 2018-11-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

Also Published As

Publication number Publication date
AU2018380765A1 (en) 2020-06-11
US20200369754A1 (en) 2020-11-26
CA3084098A1 (en) 2019-06-13
CN111447951A (en) 2020-07-24
EA202091350A1 (en) 2020-09-02
EP3720490A1 (en) 2020-10-14
KR20200094177A (en) 2020-08-06
JP2021505142A (en) 2021-02-18
WO2019110571A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
IL273631A (en) Hpv-specific binding molecules
IL275510A (en) Ror1-specific antigen binding molecules
IL263715A (en) Lag -3 binding members
IL274371A (en) Molecules that bind to cd137 and psma
HK1252862A1 (en) Antibody molecules which bind cd45
SG11202004904XA (en) Binding molecules that specifically bind to tau
HK1252791A1 (en) Binding molecules with modified j-chain
IL254223A (en) Cd20 binding molecules and uses thereof
GB201612520D0 (en) Binding molecules
GB201702091D0 (en) Specific binding molecules
SG10202111844VA (en) Cxcr4 binding molecules
IL269394A (en) Antibodies binding to steap-1
HK1258317A1 (en) Binding molecules specific for asct2 and uses thereof
IL269752B (en) Fgfr3 binding molecules
GB201820446D0 (en) Antigen binding molecules that bind light
HRP20181700T1 (en) Binding folder
GB201718735D0 (en) Bispecific molecules that bind to CD137 and PSMA
GB201508729D0 (en) Binding molecules